Evidence map›Paper›PMID 26045659›Full record

ArticleDrug design, development and therapy2015

Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin.

Ran Liu, Yonglu Wang, Xueming Li, Wen Bao, Guohua Xia, Wei Chen, Jian Cheng, Yuanlong Xu, Liting Guo, Baoan Chen

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Ran LiuDepartment of Hematology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, People's Republic of China ; Faculty of Oncology, Medical School, Southeast University, Nanjing, People's Republic of China.
Yonglu WangDepartment of Hematology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, People's Republic of China ; College of Pharmacy, Nanjing University of Technology, Nanjing, People's Republic of China.
Xueming LiCollege of Pharmacy, Nanjing University of Technology, Nanjing, People's Republic of China.
Wen BaoDepartment of Hematology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, People's Republic of China ; Faculty of Oncology, Medical School, Southeast University, Nanjing, People's Republic of China.
Guohua XiaDepartment of Hematology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, People's Republic of China ; Faculty of Oncology, Medical School, Southeast University, Nanjing, People's Republic of China.
Wei ChenCollege of Pharmacy, Nanjing University of Technology, Nanjing, People's Republic of China.
Jian ChengDepartment of Hematology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, People's Republic of China ; Faculty of Oncology, Medical School, Southeast University, Nanjing, People's Republic of China.
Yuanlong XuCollege of Pharmacy, Nanjing University of Technology, Nanjing, People's Republic of China.
Liting GuoDepartment of Hematology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, People's Republic of China ; Faculty of Oncology, Medical School, Southeast University, Nanjing, People's Republic of China.
Baoan ChenDepartment of Hematology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, People's Republic of China ; Faculty of Oncology, Medical School, Southeast University, Nanjing, People's Republic of China.
Zhongda Hospital Southeast University · CNNanjing Tech University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To increase the encapsulation of hydrophilic antitumor agent daunorubicin (DNR) and multidrug resistance reversal agent tetrandrine (Tet) in the drug delivery system of nano-particles (NPs), a functional copolymer NP composed of poly(lactic-co-glycolic acid) (PLGA), poly-L-lysine (PLL), and polyethylene glycol (PEG) was synthesized and then loaded with DNR and Tet simultaneously to construct DNR/Tet-PLGA-PLL-PEG-NPs using a modified double-emulsion solvent evaporation/diffusion method. And to increase the targeted antitumor effect, DNR/Tet-PLGA-PLL-PEG-NPs were further modified with transferrin (Tf) due to its specific binding to Tf receptors (TfR), which is highly expressed on the surface of tumor cells. In this study, the influence of the diversity of formulation parameters was investigated systematically, such as drug loading, mean particle size, molecular weight, the concentration of PLGA-PLL-PEG-Tf, volume ratio of acetone to dichloromethane, the concentration of polyvinyl alcohol (PVA) in the external aqueous phase, the volume ratio of the internal aqueous phase to the external aqueous phase, and the type of surfactants in the internal aqueous phase. Meanwhile, its possible effect on cell viability was evaluated. Our results showed that the regular spherical DNR/Tet-PLGA-PLL-PEG-Tf-NPs with a smooth surface, a relatively low polydispersity index, and a diameter of 213.0±12.0 nm could be produced. The encapsulation efficiency was 70.23%±1.91% for DNR and 86.5%±0.70% for Tet, the moderate drug loading was 3.63%±0.15% for DNR and 4.27%±0.13% for Tet. Notably, the accumulated release of DNR and Tet could be sustained over 1 week, and the Tf content was 2.18%±0.04%. In cell viability tests, DNR/Tet-PLGA-PLL-PEG-Tf-NPs could inhibit the proliferation of K562/ADR cells in a dose-dependent manner, and the half maximal inhibitory concentration value (total drug) of DNR/Tet-PLGA-PLL-PEG-Tf-NPs was lower than that of DNR, a mixture of DNR and Tet, and DNR/Tet-PLGA-PLL-PEG-NPs. These results clearly indicate that the PLGA-PLL-PEG formulation is a potential drug delivery system for hydrophilic and hydrophobic drugs, and that Tf modification may increase its targeting properties.

Indexed as

Drug Delivery SystemsAntineoplastic AgentsBenzylisoquinolinesCell ProliferationCell SurvivalDaunorubicinDelayed-Action PreparationsDose-Response Relationship, DrugDrug CarriersDrug LiberationHumansHydrophobic and Hydrophilic InteractionsK562 CellsLactic AcidNanoparticlesParticle SizeAntineoplastic AgentsBenzylisoquinolinesDaunorubicinDelayed-Action PreparationsDrug CarriersLactic AcidPolyethylene GlycolsPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerPolylysinetetrandrineTransferrindaunorubicinPEGPLGAPLLtetrandrine

Identifiers

PMID26045659
PMCPMC4448924
OpenAlexW1769001866

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.